The company issued an interim convertible note for $100,000 to BV Advisory Partners, LLC on March 23, 2026. This $100,000 loan is the first tranche of a contemplated $500,000 financing commitment from BV Advisory Partners, LLC. The interim loan is non-interest bearing and has a maturity date of six months from issuance. Upon consummation of a business combination, the outstanding principal may be converted into shares of the combined entity at a 35% discount to the market price. Proceeds from the interim loan will be used for accounting, audit, Nasdaq compliance, legal, proxy, extension, and other regulatory and transaction-related expenses. The company's original sponsor, Drugs Made in America Acquisition LLC, is non-operational and subject to legal constraints. BV Advisory Partners, LLC introduced a potential business combination opportunity involving an enterprise technology platform focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity solutions. The company has commenced preliminary due diligence on this potential opportunity, but no definitive agreement has been executed. The second tranche of $200,000 from the financing commitment is expected within 21 days of March 23, 2026, with the remainder on an as-needed basis. The company agreed to use commercially reasonable efforts to provide the Investor with not less than 40% of the economic benefit equivalent to sponsor-level economics.